Brytly is the first nonprescription eye drop that contains apraclonidine, and the Food and Drug Administration approved it on Friday, October 16, 2026. Alcon holds the approval for the 0.125 percent solution, which is labeled for relief of eye redness caused by minor irritations. Higher-strength apraclonidine has until now been a prescription-only medicine.
Help yourself and the planet: The Cool Down makes it easy to help yourself while helping the planet, with smart, simple changes to save more and waste less in your everyday life.
We may earn a commission if you sign up.
Apraclonidine 0.125 percent from Alcon
Brytly is apraclonidine ophthalmic solution at a 0.125 percent concentration, and the agency says it is meant for adults and children 12 years of age and older. Redness, the agency explains in its announcement, is most often caused by swollen or dilated blood vessels on the surface of the eye, and the label covers redness due to minor irritations such as dryness or dust. The approval is for a single, narrowly worded purpose, which is temporary relief of that redness, and the drop is not a treatment for any underlying eye disease.
The dosing limit is firm: no more than two times per day.
Apraclonidine itself is an old molecule in eye care. Drug Topics describes it as an alpha-2 adrenergic agonist that lowers pressure inside the eye by reducing the production of fluid there. Neither that report nor the FDA page explains how that pharmacology translates into a whiter-looking eye at the lower strength, so the mechanism behind the redness claim is left to the label and to Alcon to describe, and nothing in the reviewed sources should be read as showing how well the drop works compared with other redness products.
The prescription parent and the approval route
The FDA announcement notes that apraclonidine at higher concentrations is available by prescription to reduce eye pressure in patients with glaucoma or those undergoing certain laser eye surgeries. That detail matters for reading the news correctly: the prescription version is not an eye-redness product, so Brytly is a lower-strength nonprescription use of the same active ingredient. Trade outlet Drug Topics identifies the prescription source as Iopidine, an apraclonidine 1 percent product that Harrow Health commercialized in June 2022 to prevent pressure spikes after laser eye procedures, and says the two differ in dosing.
The FDA’s text does not state which application type Alcon used, and it does not name Iopidine, so those points rest on the trade report. What the agency’s page on the nonprescription drug application process does say is that a drug can be marketed as nonprescription through an application reviewed by the FDA, including when a sponsor seeks to move a product first approved as prescription. Whether Brytly was formally an NDA supplement or a new application is therefore not confirmed here, and no company statement was available to settle it.
What Mike Davis said for the agency
The announcement quotes Mike Davis, M.D., Ph.D., director of the FDA’s Center for Drug Evaluation and Research, who said, “Expanding access to safe and effective nonprescription treatments is a priority for FDA.” Davis also described the approval as giving consumers a new nonprescription option to manage eye redness, without a visit to a health care provider as the first step. The page ties the decision to the agency’s Public Health Pillars, which prioritize affordable access to medicines, and says the FDA is working to encourage competition and widen the range of nonprescription drugs on the market.
Neither the FDA page nor the trade report gives a date when Brytly will reach drugstore shelves or a price, so any launch timing and cost remain unannounced in the sources reviewed.
Label limits: two drops a day, three days, lenses out
For consumers, the change is about where the decision gets made. A redness drop with this ingredient no longer requires a prescription, so the package and its Drug Facts panel carry the job of conveying limits that a clinician would otherwise explain, which is why the age floor of 12, the two-a-day ceiling and the three-day cutoff are written as hard stops and not suggestions.
The conditions of use are the practical content of the approval. People who wear contact lenses should remove them before using the drop and wait at least 10 minutes after applying it before putting them back in, and anyone using other eye drops should wait five minutes between products. The agency tells consumers to read the full Drug Facts label before use, the standard panel that lists active ingredient, uses, warnings and directions on nonprescription medicines.
The stop-use rules are specific. In the FDA’s words, “Consumers should stop using Brytly and ask a doctor if they experience eye pain, changes in vision,” and the same advice applies if redness or irritation continues, if the condition worsens, or if it lasts more than three days. That ceiling is a signal in itself: a drop approved for minor irritation is not meant to mask a problem that does not clear up. Readers who want the ingredient’s general profile can find it in the National Library of Medicine’s apraclonidine drug information.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
Help yourself and the planet: Get The Cool Down →
We may earn a commission if you sign up.
More from Morning Overview
- Lake Powell sank to a record 3,517 feet, nearing the level that stops Glen Canyon Dam’s turbines
- Seven of Earth’s nine planetary boundaries are breached, and all seven are worsening
- The NSA says three phone features should be off whenever you aren’t using them
- Hurricane Hunter radar shows four warning signs that a tropical cyclone is about to strengthen, a University of Miami study found
